Recent developments in the management of Huntington's disease

Area of Science:

• Neuroscience
• Genetics
• Pharmacology

Background:

• Huntington's disease (HD) is a rare, inherited neurodegenerative disorder.
• Current treatments focus on symptom management, primarily chorea, with limited FDA-approved options.
• No disease-modifying treatments are currently available for HD.

Purpose of the Study:

• To review the clinical pipeline of small molecule drugs for Huntington's disease.
• To discuss molecular targets and emerging therapeutic strategies, including gene therapy.
• To provide an overview of ongoing clinical and observational studies for HD.

Main Methods:

• Literature review of clinical trials and research publications on Huntington's disease therapeutics.
• Analysis of the current small molecule drug pipeline and identified molecular targets.
• Compilation of data on ongoing interventional and observational studies.

Main Results:

• Over 200 clinical studies are underway for HD, with 75% being interventional.
• Numerous small molecules and gene therapies are in various stages of clinical investigation.
• Drug repurposing is a key strategy in the search for novel anti-HD agents.

Conclusions:

• The therapeutic landscape for Huntington's disease is expanding with diverse approaches.
• Continued research into molecular targets, small molecules, and gene therapies offers hope for future treatments.
• Biomarkers, diagnostics, and behavioral studies are crucial for comprehensive HD management and research.